Machine perfusion technology is nearing the point of rescuing discarded liver grafts in the hope of proving them to be or improving them to the point of being transplantable. However, there are no validated metrics to determine transplantability after machine perfusion. This study involves collecting biopsies from transplanted livers before and after implantation to correlate metabolite and gene expression with post-transplant function. This data will help develop a viability index for machine perfused livers.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
60
For measurement of tissue co-factor levels, we will take needle biopsies of transplanted livers immediately after procurement, immediately prior to implantation (at the end of preservation), 30 minutes after portal vein reperfusion, and 30 minutes after hepatic artery reperfusion. For those livers that have more than 60 minutes between portal vein and hepatic artery reperfusion, an additional biopsy will be performed at 60 minutes after portal vein reperfusion. Post-procurement biopsies will be collected regardless of where the liver was obtained.
Massachusetts General Hospital
Boston, Massachusetts, United States
RECRUITINGPeak transaminase value post transplant
The primary endpoint is peak transaminase values since transaminase elevation is a marker of hepatocyte injury
Time frame: 1 Year
Acute Liver Rejection
Time frame: 1 Year
Incidence of major Infection
Time frame: 1 Year
Hepatitis C Recurrence (in Hepatitis C positive recipients)
Time frame: 1 Year
Kidney Failure
Time frame: 1 Year
Biliary Complications
Time frame: 1 Year
Liver Graft Failure
Time frame: 1 Year
Death
Time frame: 1 Year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.